ALEXION PHARMACEUTICALS, INC.

ALEXION PHARMACEUTICALS, INC. logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public, Subsidiary
Established
1992-01-01
Employees
3.8K
Market Cap
-
Website
http://www.alexion.com
Clinical Trials
Related News

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

First Posted Date
2020-09-25
Last Posted Date
2024-12-10
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
120
Registration Number
NCT04564339
Locations
πŸ‡¬πŸ‡§

Research Site, Salford, United Kingdom

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ALXN1840
Drug: Placebo
Drug: Moxifloxacin
First Posted Date
2020-09-23
Last Posted Date
2023-08-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
57
Registration Number
NCT04560816
Locations
πŸ‡ΊπŸ‡Έ

PPD Development, LP, Austin, Texas, United States

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Phase 3
Active, not recruiting
Conditions
Thrombotic Microangiopathy
Interventions
Drug: Ravulizumab
Other: Best Supportive Care
First Posted Date
2020-09-22
Last Posted Date
2024-08-15
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
41
Registration Number
NCT04557735
Locations
πŸ‡¬πŸ‡§

Research Site, Newcastle Upon Tyne, United Kingdom

A Study of the Effects of Food and Age on Danicopan

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Danicopan
First Posted Date
2020-09-16
Last Posted Date
2023-01-13
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
27
Registration Number
NCT04551599
Locations
πŸ‡ΊπŸ‡Έ

Clinical Trial Site, Tempe, Arizona, United States

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy
First Posted Date
2020-09-16
Last Posted Date
2021-12-28
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
28
Registration Number
NCT04551586
Locations
πŸ‡ΊπŸ‡Έ

Clinical Trial Site, Lincoln, Nebraska, United States

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

First Posted Date
2020-09-10
Last Posted Date
2024-12-18
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
130
Registration Number
NCT04543591
Locations
πŸ‡¬πŸ‡§

Research Site, Wirral, United Kingdom

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

Phase 1
Completed
Conditions
Wilson Disease
Interventions
Drug: ALXN1840
Drug: Celecoxib
First Posted Date
2020-08-25
Last Posted Date
2023-08-21
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
36
Registration Number
NCT04526197
Locations
πŸ‡ΊπŸ‡Έ

Clinical Trial Site, Austin, Texas, United States

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Phase 1
Completed
Conditions
Wilson Disease
Interventions
Drug: Bupropion Hydrochloride
Drug: ALXN1840
First Posted Date
2020-08-25
Last Posted Date
2023-08-31
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
54
Registration Number
NCT04526210
Locations
πŸ‡ΊπŸ‡Έ

Clinical Trial Site, Austin, Texas, United States

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

First Posted Date
2020-08-13
Last Posted Date
2024-10-04
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
267
Registration Number
NCT04512235
Locations
πŸ‡¬πŸ‡§

Research Site, London, United Kingdom

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

First Posted Date
2020-08-07
Last Posted Date
2024-10-18
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
124
Registration Number
NCT04504825
Locations
πŸ‡¬πŸ‡§

Research Site, London, United Kingdom

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy